Nanjing King-Friend Biochemical PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 5/6
Nanjing King-Friend Biochemical PharmaceuticalLtd has a total shareholder equity of CN¥6.3B and total debt of CN¥2.3B, which brings its debt-to-equity ratio to 36.7%. Its total assets and total liabilities are CN¥9.4B and CN¥3.2B respectively.
Key information
36.7%
Debt to equity ratio
CN¥2.30b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.95b |
| Equity | CN¥6.27b |
| Total liabilities | CN¥3.16b |
| Total assets | CN¥9.43b |
Recent financial health updates
Would Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Be Better Off With Less Debt?
Sep 30
Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Is Making Moderate Use Of Debt
Jun 26Recent updates
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Popularity With Investors Is Under Threat From Overpricing
Nov 27Would Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Be Better Off With Less Debt?
Sep 30Investors Still Waiting For A Pull Back In Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707)
Aug 26Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Is Making Moderate Use Of Debt
Jun 26Getting In Cheap On Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Might Be Difficult
May 26Financial Position Analysis
Short Term Liabilities: 603707's short term assets (CN¥6.9B) exceed its short term liabilities (CN¥2.2B).
Long Term Liabilities: 603707's short term assets (CN¥6.9B) exceed its long term liabilities (CN¥936.8M).
Debt to Equity History and Analysis
Debt Level: 603707's net debt to equity ratio (5.5%) is considered satisfactory.
Reducing Debt: 603707's debt to equity ratio has reduced from 39.6% to 36.7% over the past 5 years.
Debt Coverage: 603707's debt is well covered by operating cash flow (65.3%).
Interest Coverage: Insufficient data to determine if 603707's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Yong Jian Li | China Merchants Securities Co. Ltd. |
| Shitong Han | Citic Securities Co., Ltd. |